Biopharma Predicts ‘Significant’ R&D Reductions With Medicare IPI Model
Manufacturers refute Administration claims that Medicare International Pricing Index model will have minimal impact on industry innovation.
Manufacturers refute Administration claims that Medicare International Pricing Index model will have minimal impact on industry innovation.